...
首页> 外文期刊>International Journal of Neuroscience >Investigating the possible pain attenuating mechanisms of pregabalin in chronic constriction injury-induced neuropathic pain in rats
【24h】

Investigating the possible pain attenuating mechanisms of pregabalin in chronic constriction injury-induced neuropathic pain in rats

机译:研究普瑞巴林在慢性收缩损伤诱导的大鼠神经治疗中可能的疼痛衰减机制

获取原文
获取原文并翻译 | 示例
           

摘要

Aim of the study: The current study was aimed to investigate the neuropathic pain attenuating mechanism of pregabalin using chronic constriction injury (CCI) model in rats. Material and Methods: The sciatic nerve was ligated by placing four loose ligatures around it to induce neuropathic pain. The pain development in terms of cold allodynia, mechanical hyperalgesia, and heat hyperalgesia was assessed on the 7th and 14th day after surgery, using acetone drop, pinprick, and hot plate tests. On the 14th day after the injury, pain parameters were assessed 30 minutes after administration of pregabalin (30 mg/kg) and sodium nitroprusside (5 mg/kg) in CCI-subjected rats. Results: CCI led to induction of neuropathic pain, which was more prominent on 14th day in comparison to 7th day. A single administration of pregabalin and sodium nitroprusside on 14th day, markedly reduced pain parameters and increased serum nitrite levels. Pretreatment with L-NAME abolished neuropathic pain attenuating effects of pregabalin suggesting that pregabalin may increase the levels of nitric oxide to mitigate neuropathic pain. Pretreatment with naloxone significantly abrogated pain attenuating effects of pregabalin and sodium nitroprusside in CCI-subjected rats suggesting that pregabalin and nitric oxide-mediated analgesic action are mediated through release of endogenous opioids. Moreover, naloxone failed to modulate pregabalin-induced increase in nitric oxide levels suggesting that the opioid system does not control the nitric oxide levels, and opioids may be downstream modulators of nitric oxide. Conclusion: Pregabalin may increase the release of nitric oxide, which may increase the release of endogenous opioids to attenuate neuropathic pain in CCI subjected rats.
机译:该研究的目的:目前的研究旨在探讨使用大鼠慢性收缩损伤(CCI)模型的PREGABALIN的神经疗法疼痛衰减机制。材料和方法:通过将四个松散的韧带诱导神经性疼痛来连接坐骨神经。在手术后的第7和第14天,使用丙酮滴,拼接和热板测试,评估了冷异步性,机械痛觉病毒和热痛觉患者的疼痛发展。在损伤后的第14天,在CCI对大鼠施用普瑞巴林(30mg / kg)和硝普钠(5mg / kg)后30分钟评估疼痛参数。结果:CCI导致诱导神经病疼痛,第14天比较突出至第7天。 14天的单一施用普瑞巴林和硝普钠,疼痛参数明显减少,血清亚硝酸盐水平增加。预处理L-name废除了普瑞巴林的神经疗法疼痛效果,提示普瑞巴林可能增加一氧化氮水平,以减轻神经性疼痛。通过释放内源性阿片类药物释放,通过纳尔甲蛋白酶和硝普替辛和硝普钠和硝普钠钠的疼痛衰减作用显着消除了血红蛋白和硝普钠的疼痛衰减作用。通过释放内源性阿片类药物介导。此外,纳洛酮未能调节普瑞巴林诱导的一氧化氮水平的增加,表明阿片类药物不控制一氧化氮水平,并且阿片类药物可以是一氧化氮的下游调节剂。结论:普瑞巴林可能增加一氧化氮的释放,这可能增加内源阿片类药物的释放,以衰减CCI受体大鼠的神经病疼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号